Comparison of resection, liver transplantation and transcatheter oily chemoembolization in treatment of hepatocellular carcinoma
References (44)
- et al.
Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis
Gastroenterology
(1990) - et al.
Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome
J Hepatol
(1993) - et al.
Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
Gastroenterology
(1989) - et al.
Primary treatment of hepatocellular carcinoma by arterial chemoembolization
Am J Surg
(1992) - et al.
Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma
Gastroentrology
(1993) - et al.
Asymptomatic hepatocellular carcinoma in Child's A cirrhosis: a comparison of natural history and surgical treatment
Gastroenterology
(1989) - et al.
Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer
Ann Surg
(1984) - et al.
Ultrasonically guided subsegmentectomy
Surg Gynecol Obstet
(1985) - et al.
Liver resection in cirrhotic patients: a Western experience
World J Surg
(1986) - et al.
Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma
Surgery
(1986)
Clinical experience with 118 hepatic resections for hepatocellular carcinoma
Surgery
Hepatic resection for hepatocellular carcinoma. Clinical features and long term prognosis
Ann Surg
Clinical experience with hepatic resections for hepatocellular carcinoma in patients with cirrhosis
Surg Gynecol Obstet
Hepatic researction in 120 patients with hepatocellular carcinoma
Arch Surg
Surgery of smell hepatocellular carcinoma. Analysis of 144 cases
Cancer
Preoperative estimation of surgical risk of hepatectomy in cirrhotic patients
Hepatogastroenterology
Hepatic resection for hepatocellular carcinoma
Surgery
Associations Francaises de Recherche en Chirurgie. Résection des carcinomes hépatocellulaires. Analyse des facteurs pronostiques d'une série multicentrique de 153 malades
Gastroenterol Clin Biol
Liver transplantation for malignant disease. Results in 93 consecutive patients
Ann Surg
Primary hepatic malignancy: the role of liver transplantation
Br J Surg
Hepatic transplantation for primary and metastatic cancers of the liver
Surgery
Liver transplantation for primary hepatic cancer
Transplantation
Cited by (97)
Changes of long-term survival of resection and liver transplantation in hepatocellular carcinoma throughout the years: A meta-analysis
2024, European Journal of Surgical OncologyVolume perfusion computed tomography (VPCT) - Based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation
2015, European Journal of RadiologyCitation Excerpt :Different particle sizes have been tested so far as well as different drugs and variable doses in order to optimize this technique [7,9,10]. One major limitation to repeated TACE is severe hepatic dysfunction due to the higher risk for post-interventional complications and poor prognosis in patients with Child-Pugh class C disease [11]. Post-TACE liver atrophy, lobar or focal, depends on the extent of the embolization area and was described in patients undergoing TACE.
Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations
2015, HPBCitation Excerpt :Although some of these therapies have been used for many years as standard, their efficacy is still being questioned. Results from prospective studies comparing TACE with absence of treatment were not consistent across studies,6-12 whereas all retrospective studies reported a survival benefit with TACE.13-15,17 However, the level of evidence of the latter studies is lower.
Liver transplantation versus liver resection for hepatocellular carcinoma: A meta-analysis
2014, Hepatobiliary and Pancreatic Diseases InternationalSuperselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function
2012, European Journal of RadiologyCitation Excerpt :Bronowicki et al., Yoshimi et al., and Huang et al. retrospectively compared the result of TACE and with that of surgical resection for resectable HCC. The 5-year overall survival rates were not significantly different between 2 groups (34%–47% for TACE and 28%–43% for surgical resection) [21–23]. In this study, we collected a large sample of patients and focused on resectable early-stage HCC patients with Child-Pugh A liver function.
Stereotactic body radiotherapy for primary hepatocellular carcinoma
2011, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Equally notable, and perhaps more clinically relevant, is the median TTP of 4 years for the entire cohort and 3 years for the nontransplanted population. These rates are comparable to those obtained with percutaneous ablation and surgical resection, and they exceed the quoted rate of 10 to 27 months after transarterial chemoembolization or radioembolization for similarly sized lesions (19, 23, 24). The impact on overall survival relative to other liver-directed therapies remains to be determined.